Renal cell cancer (RCC) represents 2-3% of all cancers, with the highest reported incidence in Western countries [1]. Due to the increased incidental detection of tumours by cross-sectional imaging performed for other non-specific reasons, RCC incidence has progressively increased in the last few decades by about 2% worldwide [1]. Such increasing incidence occurred also in Europe where it was estimated that in 2012 there were approximately 64,400 new cases of RCC and 34,700 RCC-related deaths [1].

RCC is usually diagnosed when it is still a kidney-confined disease (i.e. T1), and in most of the cases its largest diameter measures no more than 4 cm (i.e. T1a).

Partial nephrectomy (PN) represents the gold standard treatment for T1 RCC. However, in the last two decades percutaneous image-guided thermal treatments such as radiofrequency ablation (RFA) and cryoablation (CA) were increasingly proposed for patients unfit for surgery, and a large retrospective study has recently reported similar rates of local tumour control after percutaneous thermal treatments and PN applied to treat T1 RCC [2].

Nevertheless, percutaneous treatments are still struggling to affirm their primary curative role in T1 RCC patients and in fact, they still do not appear as the first-line treatment option in the guidelines published by the largest uro-oncological societies (3-5). This is likely due to the low-quality evidence gathered in last two decades, which was often derived from small single-arm retrospective case series (6-11), which were more focused on the technical aspects of the treatment rather than on the whole clinical/ontological scenario of the disease. Looking back to these studies, some common weaknesses may be seen and include: a) the heterogeneity of protocols in terms of ablation system, imaging guidance and imaging protocols used to assess the clinical result; b) the lack of a systematic inclusion of so-called “biopsy-proven” RCCs; and c) the absence of systematic reporting of the RCC Fuhrman grade. Despite all these limitations, it should be noted that these studies did not fail in demonstrating all the main potentialities granted by the percutaneous thermal treatments such as the reduced complication rate compared to PN, the reduced in-hospital stay, and the optimal rates of local tumour control, especially when T1a tumours were treated.

Given such scenarios, it is expected that in the next few years, percutaneous treatments will still continue to play a major role in the treatment of T1 RCC in patients unfit for surgery, and more and more they will be probably be proposed to, or even requested by, good surgical candidates. However, it seems time to clearly establish the primary curative intent of percutaneous treatments for T1 RCC through an official acceptance of these treatments by the major international guidelines. Therefore, it will be mandatory to apply a systematic approach taking into account:

1) A rigorous patient selection limited to “biopsy-proven”, low Fuhrman grade RCCs (the selection should pass through an accredited and dedicated tumour board).

2) A systematic and widely-accepted application of one single ablation technique, in this sense CA seems the most adapted tool since: a) is particularly designed to shape the ablation area according to the size and morphology of the target tumour; b) allows immediate intra-operative visual assessment of the technical success (i.e. large coverage of the tumour by the ice ball); c) results in low rates of urinary complications; d) is widely recognised and accepted by the urology community. Finally, CA seems particularly adapted to take advantage of machine learning-based software that will be progressively introduced into ordinary clinical practice and that will allow reproducible treatments according to tumour volume, vascularisation, location and histology (grade).
In summary, we believe that a standardisation of the protocols and quality control should be applied at each single step of the management of the RCC disease in order to gather uniform data which can be used to generate high-quality scientific evidence supporting percutaneous ablation as a first-line treatment for T1 RCC. We believe there is no other way to achieve such a goal, and this belief is supported by the successful experience of radiation therapy that has become a gold-standard treatment in many oncologic scenarios thanks to the systematic application of shared and uniform protocols.

In order to create a framework for IO to thrive and develop congruently throughout the reputation of IO as the fourth pillar in oncology care, support quantifiable benchmarks and evidence-based clinical practice guidelines, it is necessary to reinforce and further bolster IO research, both fundamental and translational. As a first step in this direction CIRSE has established a task force to promote IO within the growing immuno-oncology field. The aptly named IO4IO Task Force aims at expanding design trials integrating IO in immune-oncology field, establishing partnerships with the pharmaceutical industry, and supporting research, both fundamental and translational. As a first step in this direction CIRSE has been invited to design a joint session with ESMO at their Immuno-Oncology Congress from December 11 to 14, 2019 in Geneva, Switzerland.

Patient Information

In a continued effort to inform the public about the many benefits of interventional radiology, CIRSE recently overhauled the patient information section on its website, featuring numerous pages on IO treatments. In addition, new patient information info sheets are being created and will be available for download soon.

www.cirse.org/patients

Strategies for interventional oncology development – the CIRSE IO initiatives

Interventional oncology has experienced continuous growth over the years, the demand for procedures offered by IO sometimes outpacing the ability of hospitals and educational systems to adapt correspondingly. In order to create a framework for IO to thrive and develop congruently throughout Europe, CIRSE has launched a number of initiatives. These multifaceted projects aim to set the highest standards for all aspects of interventional oncology, from techniques to procedural and clinical care standards to teaching the various IO procedures to the next generation of IOs.

With its dedicated Oncology Alliance Subcommittee, CIRSE created an advisory body within the society to counsel the Executive Committee on all oncology-related initiatives, including its cooperation with prestigious societies such as ECOOD and ESOM, and a great number of other projects like CIRSE’s various clinical registries on IO procedures, the recently released European Curriculum and Syllabus for IO, CIRSE Library e-modules, and a special CVR supplement.

The European Curriculum for IO – Setting a common standard for IO education

This curriculum is a supplementary document that is dedicated specifically to interventional oncology and is intended to be used in conjunction with the European Curriculum and Syllabus for Interventional Radiology. It provides recommendations and guidelines for the knowledge, skills and competencies essential to attaining proficiency in IO and providing optimal IO care to cancer patients. It is intended to reinforce and further bolster the reputation of IO as the fourth pillar in cancer care.

www.cirse.org/curricula

The European Conference on Interventional Oncology – ECIO

In order to provide a platform for the ever-growing number of interventionists involved in oncology, CIRSE organised the first European Conference on Interventional Oncology in 2008 in Florence, Italy. It was a resounding success, the scientific content, the quality of the presentations and the overall number of delegates exceeding all expectations, which is why after its second edition, ECIO changed from being a biennial meeting to taking place on a yearly basis, quickly becoming a fixture in the interventional radiological and oncological calendar. Today, ECIO welcomes over 1,450 delegates from all over the globe to cutting-edge conferences held around Europe. Thanks to CIRSE’s Collaborating Against Cancer Initiative, ECIO delegates are able to bring their non-radiologist colleagues at no extra cost, helping interventional oncologists to promote multidisciplinary teamwork.

www.ecio.org

References:

6. European Conference on Interventional Oncology – ECIO

www.ecio.org

ECIO 2020

European Conference on Interventional Oncology

April 26-29

Nice, France

www.ecio.org

Special Edition / CIRSE 2019 – Barcelona

Monday, September 9, 2019

2

>>
Immunotherapy: big business vs. evidence

Daniel Y. Sze

Decades of study on the immune system and its role in suppressing malignancy have finally yielded effective pharmacological prescription to treat cancer. The idea of manipulating a patient’s immune system to promote its recognition and attack the patient’s cancer is extremely compelling, and the introduction of these agents into the commercial market was met with very rapid adoption. These new immunotherapy agents include: checkpoint inhibitors, a type of agent that boosts anti-tumour immunity by reducing some of the restraints on immune cells; CAR-T cells, tailored human T lymphocytes that are taught to recognise and attack a cancer; and oncolytic viruses, engineered to selectively infect cancer cells and trigger anti-tumour immunity. These new agents have been proven in large clinical trials to be efficacious against a wide variety of malignancies, with improvement of survival and tolerable toxicity rates. It is particularly exciting that a substantial number of patients have very durable responses for many years, suggesting that even in late stages, some malignancies may be permanently cured.

The 2018 Nobel Prize in Physiology or Medicine was shared by two researchers, James Allison and Tasuku Honjo, who discovered co-stimulatory checkpoints that allow for tumour immunity by reducing some of the other immune mechanisms that are being tested as targets for current immunotherapies, but 61% of all human clinical trials, 23 are in Phase III or later. The median trial duration in oncology is approximately 3.5 years, so progressing through Phases I, II and III is lengthy, and the median time from a drug receiving a patent to being launched commercially is over 10 years. To achieve success rate for drugs entering human Phase I trials eventually reaching approval stands at only 5% to 6% according to a research and development price tag of approximately €2 billion per successful drug.

The two top-selling PD-1 checkpoint inhibitors, pembrolizumab and nivolumab, are each responsible for approximately €6 billion in sales annually - the sales of these two drugs alone are equivalent to the annual total healthcare expenditure of the Czech Republic with a population of over 10 million people. Sales of these two drugs also represent nearly 10% of the total global expenditure on cancer drugs, which reached €132 billion in 2018. Per gram, these drugs cost approximately 5,000 times the price of gold, and treatment of a typical American patient costs about €130,000 per year. In the year 2018, over 200,000 individual patients were treated globally with a PD-1 or PD-L1 inhibitor, despite limited availability outside of Western Europe and North America.

CAR-T cells are even more costly, approximately €400,000 per patient. Only two are currently approved, but an additional 24 CAR-T cell therapies are in late stages of human clinical trials. Other adoptive cell transfer technologies (including dendritic cell vaccine, NK cell, cytotoxic T lymphocyte, tumour-infiltrating lymphocyte, mesenchymal stem and progenitor cell therapies) account for another 30 drugs in the late-stage pipelines. Although these technologies are exciting and promising, and may provide real benefit to patients, it is difficult to budget for an additional 400,000 per cancer patient over that patient’s treatment course.

Melanoma is the human malignancy that has been the proving ground for most immunotherapies, in part because of its high tumour mutational load, making it susceptible to immune system recognition and response. The mean total cost of management of malignant melanoma was €6,134 per patient in 2004, and escalated to €99,682 in 2017, in part because immunotherapy is given as first-line therapy in almost 80% of patients. A study in 2019 showed the addition of the oncolytic virus talimogene laherparepvec increased the cost further to €439,060. This represented an incremental cost utility ratio of 2,007,065 per progression-free survival quality-adjusted life year (PFS-QALY) gained. The survival improvement, though, was statistically significant.

Certainly, immunotherapy is revolutionising the way we treat cancer, with particular benefit to the 15–20% of patients with durable, long-term responses. It is problematic to assign a cost to human life. The financial burden of immunotherapy, however, is threatening already stretched medical systems, and is not sustainable. The €132 billion spent globally on cancer drugs in 2018 represented a doubling in 5 years, and projections show another doubling in the next 5–6 years. Pharmaceutical companies deserve a return on their substantial investments in research and development, but eligible patients deserve treatment without falling into bankruptcy. The average annual cost of a newly approved drug is €132,000, and some patients receive more than one. Even beyond the science, we will need to devise new ways to apply immunotherapy in rational, and sustainable algorithms.
ESRD Symposium

Novel interventional technology for dialysis patients
Experts weigh in on new data, guidelines, and what to incorporate into treatment paradigms

Date: Monday 9th September  
Time: 14:30 - 15:30  
Location: Room 117  
Moderator: Dr. Robert Morgan

<table>
<thead>
<tr>
<th>Agenda</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient challenges and new KDOQI guidelines</td>
<td>Dr. Charmaine Lok  Canada</td>
</tr>
<tr>
<td>Endo AVF, the evidence and patient benefits</td>
<td>Dr. Dheeraj K. Rajan  Canada</td>
</tr>
<tr>
<td>Endo AVF creation, the real-world experience</td>
<td>Dr. Panagiotis Kitrou  Greece</td>
</tr>
<tr>
<td>Innovative technologies for managing the patient life plan</td>
<td>Dr. Bart Dolmatch  USA</td>
</tr>
</tbody>
</table>

© 2019 BD. BD the BD Logo and all other trademarks are property of Becton, Dickinson and Company

BD Booth  
#55  
Come visit us
The newly introduced CIRSE Academy aims at providing comprehensive knowledge on IR procedures through online courses based on the European Curriculum and syllabus for IR. Courses include a theoretical part, sample cases and teaching videos, and are all peer-reviewed by experts. All CIRSE Academy courses are CME-certified and end with an interactive quiz to test your knowledge on the respective procedures.

Currently, there are 26 courses available across 7 topics, with another series of basic and advanced courses already in the production phase.

Each course takes 1-2 hours to complete and has been designed around the European Curriculum and syllabus for IR, making the CIRSE Academy the perfect tool to help you prepare for the EBIR exam. Ninety-day access can be bought for each course; CIRSE members are eligible for a reduced fee.

The courses have been carefully compiled by leaders in the field, with over fifty well-respected interventional experts contributing their time and knowledge to this momentous project. We spoke to two course authors to find out more about their experiences in working on the Academy, and why their respective modules are attracting such interest.

Dr. Maria Tsitskari, an interventional radiology consultant based in Nicosia, Cyprus, has contributed to two published Academy modules, including the most downloaded. She also serves on CIRSE Patient Information Brochure Task Force and the European Trainee Forum.

CIRSE: At the time of writing, the “Biliary drainage and stenting” module ranks as the Academy’s top viewed course – does this surprise you?

Tsitskari: Actually, it does not, since biliary procedures constitute one of the most common and basic IR procedures, and play an important part of the management of patients with both benign and malignant biliary obstruction. Despite this, biliary interventions can still present some of the most demanding and complex problems in interventional radiology, and it makes perfect sense that the IR community is looking to read up on the latest information.

CIRSE: What aspects of biliary drainage and stenting do you think are particularly important to consider?

Tsitskari: I think one important aspect of biliary drainage and stenting is proper and careful pre-procedural imaging evaluation. Pre-procedural imaging provides valuable information about the extent of biliary obstruction and dilatation, the level of obstruction and presence of any variations in biliary anatomy. Understanding the anatomy of the liver and the biliary tree is also essential when performing biliary interventions. Different variants in the bile duct anatomy exist that can have a profound effect on planning a biliary drainage procedure.

CIRSE: You have worked on two courses – how have you found the experience?

Tsitskari: I admit that the work was hard and demanding, but it was a great experience. I learned a lot through this process. Reading and, at the same time, working together with other experts in this field to compile these modules was a great opportunity to refresh and reinforce my knowledge.

CIRSE: Who do you think can benefit most from the CIRSE Academy courses?

Tsitskari: The courses are ideal for IR trainees aiming to gain fundamental knowledge of a topic, particularly when preparing to sit the EBIR exam. Moreover since education is a lifelong process, experts will also find the courses a useful tool for helping to expand their knowledge of different interventional topics. Advanced courses are also planned for the near future, which is a very exciting move!

Dr. Heather Moriarty currently works at The Alfred Hospital, Melbourne, Australia. She co-authored the module on SVC stenting for treatment of malignant obstruction with Dr. Andreas Mahnken. Dr. Moriarty is an executive member of the European Trainee Forum.

CIRSE: SVC stenting for treatment of malignant obstruction seems to be a somewhat obscure topic – how many of these cases do you see? What difference does IR make to these patients?

Moriarty: With improved multidisciplinary treatment of many tumours and prolonged patient survival, the management of oncological patients is becoming ever more complex. Interventional radiology has a central role to play in disease diagnosis, stratification and management. Interventional radiology has become one of the cornerstones in the multidisciplinary team of cancer care delivery, adjuncts to treatment, palliation and improving patient comfort and quality of life through symptom relief. The placement of an SVC stent is a procedure which can make a huge impact on patient care, allowing very rapid relief of symptoms, which untreated are frequently distressing and treatment-limiting for our patients. The benefit to patients is what makes treating those with symptomatic SVC syndrome rewarding, and the efficacy of SVC stenting for the treatment of malignant obstruction is excellent, commonly allowing patients to progress onto their systemic treatment.

CIRSE: What, for you, is the best thing about the CIRSE Academy? Why did you volunteer your time?

Moriarty: The CIRSE Academy is a fantastic resource, both to refresh and extend one’s knowledge, in particular for young interventional radiologists intending to sit the EBIR exam. The variety of topics covered is excellent and the format is engaging. I volunteered for this initiative as I value and enjoy research and teaching, CIRSE as a platform for these activities allows us to advance as clinicians and as a subspecialty through the promotion of quality academic material and the availability of up-to-date resources in our dynamic medical specialty.

The CIRSE Academy – From Curriculum to Career
Ciara Madden, CIRSE Office

The CIRSE Academy in a nutshell:
- Courses available on: interventional oncology, embolisation, venous interventions, arterial interventions and non-vascular interventions, aortic interventions, and neurointerventions.
- 25 Euros per course for members | 55 Euros for non-members
- Tailored to the European Curriculum and Syllabus used for the EBIR exam
- CME accredited (1-2 points per course)
- Each course takes 1-2 hours to complete

Please visit the CIRSE website www.cirse.org/education/cirse-academy/ or learn more about the benefits of the courses by watching our video on the CIRSE YouTube channel.
Boost occlusive capacity with fiber

Polymer fibers allow significantly fewer embolization coils to achieve acute occlusion of arteries than bare metal coils.¹

Visit our booth and ask us about new data on fibered vs. non-fibered embolization coils.


www.cvirendovascular.org

FASTEST GROWING IR ENDOVASCULAR JOURNAL

OPEN ACCESS ARTICLES

... are freely available for everyone to read and share immediately upon publication
... receive more citations
... are downloaded more often
... garner greater impact
... allow authors to retain the copyright for their work

www.cvirendovascular.org
The Role of Interventional Radiology in Gynecologic Malignancies

Maureen P. Kohi

Interventional radiologists (IRs) play a central role in the management of women with gynecologic malignancies. In most IR practices, such patients are routinely cared for throughout the different phases of their malignancy.

The first introduction to a woman with a gynecologic malignancy may be on the day of her diagnostic biopsy. While many IRs are familiar with the different techniques of image-guided biopsy, access to deep lesions within the female pelvis may be challenging due to the close proximity of the pelvic organs and the vasculature [1]. In some cases, the ultrasound-guided transvaginal approach may be more practical, particularly when the traditional transabdominal or translumbar approaches are not feasible (Fig. 1a). This approach can also be used in cases of pelvic fluid aspiration (Fig. 1b) or drain placement (Fig. 1c).

Central venous access is vital for patients with gynecologic malignancies. Peripherally inserted central catheters (PICCs) (Fig. 2a) or subcutaneous ports (Fig. 2b) are commonly used for the administration of chemotherapy, antibiotics, total parenteral nutrition and other medications, and may also be used for blood sampling, transfusions and contrast administration for imaging examinations [2]. These central venous access devices are routinely placed in an ambulatory setting and are removed when no longer needed.

Women with pelvic malignancies may present with ureteral obstruction, causing hydronephrosis, pain and potential renal functional impairment [2]. In some settings, the ureteral obstruction may also cause urosepsis. As a result, percutaneous nephrostomy tubes, nephroureterostomy tubes or ureteral stents are commonly placed for urinary diversion (Fig. 3a-c). These minimally invasive procedures may obviate surgery and can be used to optimise the patient’s clinical status to undergo different forms of oncologic and radiation therapies.

In the emergent setting, IR plays a vital role in the management of post-operative bleeding. Injury to the pelvic vasculature can result in post-operative morbidity and mortality. Extravasation from the internal iliac artery branches (Fig. 4a) or the ovarian artery (Fig. 4b) can be embolised, returning the patient to a haemodynamically stable state.

In the palliative care setting, patients with malignant pleural effusions or ascites who have undergone repeated thoracentesis or paracentesis can benefit from placement of a tunneled drainage catheter into the pleural or peritoneal cavity (Fig. 5). Tunneled drainage catheters are safe, comfortable, cost-effective, and better tolerated by patients who desire to control the drainage of fluid at home [2].

Most, if not all, IRs form a deep bond with their patients who battle the various forms of oncologic diseases. Among these special patients are the women with gynecologic malignancies. It is extremely rewarding to be able to play a central role in the care of such patients, striving to provide them with diagnosis, care, comfort and dignity.

References:

Fig. 1a: Transvaginal biopsy of a pelvic lesion.

Fig. 1b: Transvaginal aspiration of pelvic fluid.

Fig. 1c: Transvaginal drain placement into a pelvic collection.

Fig. 2a: Left-sided peripherally inserted central catheter.

Fig. 2b: Right-sided single-lumen power-injectable chest port.

Fig. 2c: Percutaneous nephrostomy tube and ureteral stent.

Fig. 3a: Right percutaneous nephrostomy tube.

Fig. 3b: Bilateral nephroureterostomy tubes.

Fig. 3c: Percutaneous nephrostomy tube and ureteral stent.

Fig. 4a: Extravasation from the branches of the left internal iliac artery.

Fig. 4b: Extravasation from the left ovarian artery.

Fig. 5: Tunneled drainage catheter placed into the peritoneal cavity in a patient with malignant ascites.
Looking after our Members!

A congress as big as CIRSE can be hectic, and we are keen to provide our members with a space where they can rest and recharge between sessions.

The Members’ Lounge offers just this, with complimentary coffee and lunch, as well as a strong wireless internet connection and plenty of seating.

You can find it on the entrance level, next to Auditorium 2 and the Poster Area.

Charging Stations

Once you’ve recharged your own batteries, take the opportunity to charge your phone – several charging stations will be available outside Auditorium 2 and next to the society booths.
Balloon angioplasty of the central outflow venous system

Panos M. Kitrou, EBIR

By definition, central veins of the upper part of the body are considered the veins distal to the junction of the axillary vein with the cephalic arch i.e. the subclavian vein, the brachiocephalic vein and the superior vena cava [1].

Although an incidental finding in many cases, central venous stenosis (CVS) could become symptomatic resulting not only in inadequate dialysis performance, but also in several other clinical findings including, but not limited to, palpitation, neck, arm or breast swelling [2]. Prior insertion of foreign materials, mainly central venous catheters, accompanied by the actual use of the access circuit for dialysis, are the main reasons leading to stenosis of central veins in dialysis patients [3]. Symptom occurrence constitutes the absolute reason for treating a central venous stenosis. Treatment of a concomitant stenosis within the circuit may result in symptomatic central venous stenosis unmasking as described by Ehrle et al. [4].

The standard of practice for interventional procedures is conventional angioplasty. Although successful, angioplasty is not durable, with patency rates as low as 28.9% at six months and 29% at 1 year; doubling when high-pressure balloons are utilised [5,6]. For a successful angioplasty result, vessel sizing is crucial. As conventional ultrasound measurements do not apply for central vein diameter calculation and intra-vascular ultrasound has limited use in everyday practice due to cost, the majority of operators will rely on digital subtraction angiography (DSA) and visual estimation. Additionally, a residual stenosis of <30% will define a successful mechanical outcome. However, such a subjective approach is highly influenced by the inability of DSA to properly evaluate luminal diameter due to turbulent flow at the edge of the vessel and the presence of parietal flow, which together with the large fluctuations in intra-thoracic pressures during expiration and inspiration, can highly affect a proper vessel diameter evaluation.

Indirect signs could then define a successful angioplasty result. Complete balloon effacement during angioplasty, disappearance of venous tributaries, and direct antegrade flow during the final angiogram are valid indirect signs. The most critical sign of angioplasty, however, is patient discomfort, that will in the majority of cases define the maximum balloon size. Immediate elastic recoil is another possible problem in central vein treatment. A recent publication by Rajan et al. however, concluded that elastic recoil, although a common finding in vascular access (as high as 16%, fifteen minutes following intervention) does not significantly affect primary patency [7]. Drug coated balloons (DCB) have been proposed as a tool to decelerate the process of restenosis and hence increase primary patency. In a proof-of-concept randomised controlled trial by our department, a significant difference was observed in favour of DCB angioplasty when compared with plain balloon angioplasty in a clinically assessed intervention free period (PCB group: 179 days vs. CBA group: 124.5 days, P=0.026) [8].

Bare metal stenting (BMS) is proposed as a bail-out option where restenosis occurs less than 3 months after CBA, with assisted patency rates between 33-56% at 1 year. SIR guidelines published in 2016, however, give a benefit on the use of covered stents over BMS in central veins (12-month primary patency-stents, 34% vs. covered stents, 54%) [9].

In this session, an overview of the available guidelines regarding balloon angioplasty will be described together with an update on the most important studies available. Special emphasis will be given to the symptoms, the different treatment options and devices, while complications will also be discussed.

References:

Important Travel Notice: September 11

Please note that September 11 is Catalonia’s national holiday. It may be more difficult than usual to get around the city, as public ceremonies will be going on throughout the day.

Traditional celebrations will take place throughout the morning in the area surrounding the Arc de Triomf.

Additionally, a mass demonstration will take place in the afternoon between approximately 15:30-19:00 in the Plaça de l’Espanya area, including Paral·lel, Creu Coberta, Tarragona, Via Cristina, Gran Via and Passeig de Gràcia. The flow of traffic and density of public transit in these areas and their surroundings will be significantly impacted.

The city police recommend using the ring route to more easily get around during this time. Delegates should allow ample transport time if they plan to connect to the airport on September 11.
Diabetes Mellitus is the fastest growing health problem worldwide and raises the risk of Peripheral Artery Disease (PAD), which can lead to lower limb amputations. Abbott offers a comprehensive portfolio of products that can help avoid many amputations and guide patients on a path to keep on walking.

ABBOTT STEP BY STEP SOLUTIONS FOR PAD TREATMENT

ACCESS & CROSS

INTRODUCERS
Engage

GUIDE WIRES
HT Command™ 14/18
HT Winn

DILATE

BALLOONS
Armada™ 14/18/35

PRESERVE

SELF-EXPANDING STENTS
Absolute Pro™
Xpert Pro™

VASULAR MVCIMETIC IMPLANT
Superia™ Stent

CLOSE

VESSEL CLOSURE
Perclose Proglide™
Suture Mediated Closure System

ASSISTED COMPRESSION
FemoStop

---


CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, refer to the Instructions for Use inside the product packaging(s) or call the Abbott Customer Service Center for more information on indications, contraindications, warnings, precautions, and adverse effects. Information contained herein is for distribution for Europe, Middle East, and Africa ONLY. Check the regulatory status of the devices before distributing in areas where CE marking is not the regulation in force. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott International BVBA
Park Lane, Ugghetstraat 28, 1118 Olen, Belgium. Tel: +32.2.716.34.11
www.accessvascular.abbott
© 2019 Abbott. All rights reserved. 1.830-3.4029-06/15-2019
Peripheral arterial disease (PAD) is an increasing burden, in Europe and worldwide. This is due to increasing risk factors, which cause the late stage of atherosclerotic disease: PAD. We all know that diabetes, obesity, hyperlipidemia and hypertension are increasing, and smoking is not decreasing.

Patients need to be treated with regard to be able to perform their daily routine if they are claudicants and, in patients presenting with critical limb ischemia, to save their legs. This goes beyond a quality of life issue: we know that patients who are able to walk without restriction can reduce their risk of cardiovascular death.

As patients with PAD have so many comorbidities, they are usually not ideal candidates for open surgery. Endovascular therapies have thus increased in numbers and are the preferred treatment option for these patients.

Different vessel beds need different treatment strategies. So far, we have found effective solutions for the pelvic vessel bed, but everything beyond this was a matter of investigation.

The main focus of endovascular revascularisation in PAD patients is undoubtedly the femoral-popliteal region. In this area the standard procedure, ‘plain old balloon angioplasty’, has not been able to produce 12-month results better than around 50% with regard to primary patency. Primary stenting with bare-metal stents improved the lesion revascularisation rates after 12 months, a high safety profile regardless of the drug dosage. Long-term follow-up confirmed this promising data.

The greatest advantage of this technology is that it is an easy-to-handle and therefore easily applicable technology, making it a straightforward addition to each cathlab. Physicians using this technology do not need extended extra training to be able to apply adequate treatment.

The second biggest advantage is the reduced necessity of bail-out stenting, so a ‘leave nothing behind’ strategy can be followed.

This promising and already-applied treatment concept was questioned by a paper in December 2018, which provided a meta-analysis of all drug-coated technologies which have produced published data.

The main conclusion of this meta-analysis of Dr. Katsanos was that there is a mortality signal after long-term follow-up if patients are treated with drug-coated technologies. The second conclusion was that this signal is dose related.

As a consequence of this publication, the FDA issued a letter to health care providers and physicians, trials were stopped and an FDA panel was held in June 2019.

In preparation for this, all industry players who have performed RCTs on drug-coated technologies in the past provided the FDA panel with patient-level data analysis, performed by independent institutions, and reviewed publications. Besides that, independent investigators looked at large sets of Medicare data on patients treated with drug-coated technologies.

The conclusion of all these analyses is that there is higher mortality, but it is not statistically significant. There appears to be no causal relationship with paclitaxel. Co-founders for increased mortality are higher age, renal insufficiency and CV morbidity. The paclitaxel dose was not associated with mortality.

Another eye-catching finding was that the better the follow-up for all treatment arms, the less difference could be found with regard to different patient subpopulations. In the Japan InPact trial, for example, there was a consistent follow-up for both groups, DCB and PGBA, over the follow-up period, and no difference in mortality could be found. A possible explanation for this finding is that the better these severely diseased patients are followed, the higher the possibility to find co-morbidities, which need to be treated to provide a better outcome. Besides that, better risk prevention regarding adherence to antiplastrer therapy, lipid-lowering drugs and further more could be addressed at follow-up visits and can influence outcome.

The FDA panel has not issued a final statement so far, but a communication issued after the panel suggested that trials which are ongoing be continued, and encourage industry and investigators to provide long-term follow-up data on patients investigated so far. A further suggestion was to continue to use drug-coated technologies in patients at high risk of restenosis, which is every patient with a lesion beyond the iliac region.

The main impact of this story will be that in the future, we have to provide long-term data on patients treated with different devices to provide data on the efficacy-safety ratio.

Drug-coated-eluting technologies are indeed needed to treat the underlying disease, which is atherosclerotic disease at its most insidious.
Interventional radiologists are exposed to high levels of radiation in daily practice and therefore face particular health risks. Join us at the Radiation Protection Pavilion and learn how to reduce and protect against exposure as well as the health hazards linked to high levels of occupational exposure to radiation with our best-practice guides and information materials; or take a seat and listen to a brief talk hosted by our Subcommittee or industry partners.

### Today’s RPP Radiation Safety Talks

<table>
<thead>
<tr>
<th>Time</th>
<th>Radiation Safety Talks</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 09:45</td>
<td>Radiation protection issues in transhepatic interventions</td>
<td>B. Gebauer (Berlin/DE)</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Dose management and quality enhancement capabilities of Digital Variance Angiography</td>
<td>J. Kiss (Budapest/HU)</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>The benefits derived from the use of dose monitoring and management systems</td>
<td>G. Bartal (Kfar-Saba/IL)</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Image quality based dose regulation – how an innovative approach has changed my daily practice</td>
<td>B. Meyer (Hannover/DE)</td>
</tr>
<tr>
<td>12:30 – 12:45</td>
<td>IAEA perspectives of radiation protection in fluoroscopically guided interventions</td>
<td>J. Vassileva (Vienna/AT)</td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td>Peak Skin Dose as trigger level to implement dose optimization during embolisation procedures and support patient follow up</td>
<td>A. G. Rampoldi (Milan/IT)</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Radiation protection in percutaneous vertebral augmentation</td>
<td>K.E. Wilhelm (Bonn/DE)</td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>Using simulation to teach basic C-arm skills</td>
<td>Z. J. Haskal (Charlottesville, VA/US)</td>
</tr>
<tr>
<td>13:30 – 13:45</td>
<td>IAEA eLearning tools: How to improve radiation protection of patients and staff</td>
<td>J. Vassileva (Vienna/AT)</td>
</tr>
<tr>
<td>13:45 – 14:00</td>
<td>What you do affects your radiation exposure</td>
<td>F. Celén (Billdal/SE)</td>
</tr>
</tbody>
</table>
Recent advances in medical imaging and interventional tools have led to a significant increase in the number and complexity of interventional radiology procedures. Intervventional procedures usually require prolonged fluoroscopy times and a large number of cine acquisition series, delivering high radiation doses both to patients and staff. Therefore, there is increasing concern about the occurrence of deterministic and stochastic adverse effects. A number of studies have reported radiation-induced skin injuries in patients (including erythema, splotch, moist desquamation and dermal necrosis) and radiogenic cataracts among interventional radiologists performing fluoroscopy-guided procedures [1-3]. However, it has been reported that most of that time, the occurrence of the aforementioned adverse effects is caused by insufficient knowledge regarding radiation protection regulations and lack of radiation protection culture.

Endovascular aortic repair (EVAR) has become the most common procedure for the management of abdominal aortic aneurysm (AAA) in recent years. Despite the undisputed advantages of the technique, EVAR is associated with high radiation exposure. According to a review study, the mean radiation exposure to patients is approximately 20 mSv (range: 0.3–1000 mSv) while the radiation exposure to staff ranges from 0 to 600 μSv per procedure [4]. Moreover, an interesting article, based on GAP study analysis for the detection of DNA breaks, revealed radiation-induced DNA damage in operators performing EVAR [5]. Therefore, endovascular aortic repair/endovascular aortic repair, setting the alert for radiation dose reduction [5].

There are various ways to ensure radiation protection in the interventional suite. In recent years, radiation protection simulators have been introduced into healthcare training programs to train practitioners and, in the special case of the clinical use of ionizing radiation, to enhance knowledge, skills and abilities. Simulation training provides a virtual environment of live practical training by replicating real work experiences. Radiation protection simulation training allows trainees to learn radiation dose strategies and comprehend the factors that affect radiation dose and image quality by providing live feedback on radiation dose in a radiation-free environment.

Radiation protection training and education is addressed in the new European Directive 2013/59 Euratom [8]. The issue of education and training is considered one of the most efficient ways for achieving undisputed advantages of the technique, EVAR which provide detailed knowledge and skill requirements for health care professionals, including interventional radiologists as well as non-radiological specialists employing ionizing radiation in intervention techniques [9]. In particular, a radiation protection training programme should provide knowledge concerning radiation physics, fluoroiray equipment, the biological effects of ionising radiation, radiation protection principles, regulations and quality assurance programmes. According to Radiation Protection No 176, interventional radiologists should have the necessary skills to:

- Optimise interventional protocols according to the ALARA principle.
- Choose the best compromise between risk-benefit and radiation dose-image quality.
- Supervise the use of personal protective equipment.
- Support monitoring, evaluation and follow-up.
- Estimate effective dose and patient risk.
- Apply the relevant regulations.

Based on the training programme introduced by Radiation Protection No 173, it would be essential for each country to establish its own framework concerning radiation protection education for the certification of physicians employing ionizing radiation.

According to the literature, radiation protection training reduces radiation dose for both patients and staff, enhances the use of leaded eyeglasses and shields, improves operating practices and facilitates compliance with guidelines. Indeed, in some cases, the occupational dose decreased by approximately 55% after a radiation protection training programme. Training is the key component of implementing radiation protection and consequently it should be an integral part of the interventional radiologist’s education on a periodic basis.

References:

Fig. 1: Practical radiation protection methods in fluoroscopy-guided procedures for patients and staff
Download CIRSE 2019 in the CIRSE society app!

Your toolkit for the 2019 Annual Meeting in Barcelona:

- browse the programme
- build your personal schedule
- complete the session evaluation
- participate in e-voting polls
- send questions to the moderators
- find your way around using the interactive floor plans
- browse the list of exhibitors
- watch sessions live and on demand
- ...and much more!
Congratulations to this year’s CVIR award winners!

The prestigious “2019 Editors’ Medal” was awarded to:
Martijn R. Meijerink and Robbert S. Puijk et al.
“Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis”

Most Cited Article: Review Article
Anil Nicholas Kurup et al.
“Avoiding Complications in Bone and Soft Tissue Ablation”

Most Cited Article: Scientific Paper
Umut Ozyer
“Transcatheter Arterial Embolization with N-Butyl-2-Cyanoacrylate in the Management of Spontaneous Hematoma”

Most Cited Article: CIRSE Standards of Practice
Dimitrios K. Filippiadis et al.
“CIRSE Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System”

Most Downloaded Article
Anna-Maria Belli & Meridith Englander
“The Female Threat”

Article with the Best Media Performance
Sanne M. Schreuder et al.
“Predictive Parameters for Clinical Outcome in Patients with Critical Limb Ischemia Who Underwent Percutaneous Transluminal Angioplasty (PTA): A Systematic Review”

Outstanding Service to the Journal for the most reviews carried out in 2018
Kyung Cho, University of Michigan, USA
Ali Alsafi, Imperial College Healthcare NHS Trust, London, UK

www.cvironline.org
Single vs. double antiplatelet therapy: any evidence?
Nikolaos D. Ptohis, EBIR

Definition and incidence of PAD
Peripheral artery disease (PAD) is estimated to affect more than 200 million people worldwide (incidence 3-12%) and has high morbidity and mortality rates (1). According to the European Society of Cardiology, PAD should not be restricted to lower-extremity artery disease (LEAD), as it also includes the carotid and vertebral, upper extremities, mesenteric and renal arteries (2).

Comorbidities
Patients with PAD are at increased risk for major adverse cardiac events (MACE) (myocardial infarction (MI), ischaemic stroke and cardiovascular (CV) death) and major adverse limb events (MALE) (major amputation and acute limb ischaemia). Across the spectrum of symptomatic PAD, annual rates of MACE are 4-5%, and rates of MALE are 1-2% (3).

Indications for individualisation of therapy
It is well established that platelet activation and aggregation is associated with those adverse events, setting antiplatelet therapy as a cornerstone in the treatment of patients with PAD. Additionally, evidence suggests individualisation of antiplatelet therapy relative to clinical presentation (3). Multiple antiplatelet agents have been studied in the PAD population, including aspirin, a combination of aspirin and dipyridamole, clopidogrel, ticagrelor, cilostazol and vorapaxar (3).

Antiplatelet therapy in patients with LEAD, according to the 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases

**Fig. 1: Antiplatelet therapy in patients with LEAD [2]**

- **DAPT = dual antiplatelet therapy, SAPT = single antiplatelet therapy, VKA = vitamin K antagonist.
- a: In case of recent minor stroke or TIA. A loading dose of aspirin (300 mg) and/or clopidogrel (300/600 mg) is recommended at the acute phase of stroke/TIA or during CAS.
- b: DAPT may be considered in patients with recent acute coronary syndrome and/or percutaneous coronary intervention (<1 year), stenting of the last patent coronary artery, multiple coronary vessel disease in diabetic patients with incomplete revascularisation.
- c: Evidence is weak and bleeding doubles as compared to SAPT.
- d: Stands for as long as it is well tolerated.
- e: As the exception of patient at very high bleeding risk.
- f: DAPT may be used if another indication supersedes that of carotid artery stenting such as acute coronary syndrome or percutaneous coronary intervention of less than 1 year.
- g: In case of recent minor stroke or TIA. A loading dose of aspirin (300 mg) and/or clopidogrel (300/600 mg) is recommended at the acute phase of stroke/TIA or during CAS.
- h: Stands for as long as it is well tolerated.

ACS = acute coronary syndrome; CAD = coronary artery disease; CLTI, chronic limb-threatening ischaemia; DAT = dual anti-thrombotic therapy; LEAD = lower extremity artery disease; NDACL = non-vitamin K oral anticoagulants; OAC = oral anticoagulation; VKA = vitamin K antagonist.

* DAT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in patients with recent acute coronary syndrome and/or percutaneous coronary intervention (<1 year), stenting of the last patent coronary artery, multiple coronary vessel disease in diabetic patients with incomplete revascularisation.

**Fig. 3: Management of antithrombotic treatment in patients with carotid artery stenosis [2]**

- **DAPT = dual antiplatelet therapy, SAPT = single antiplatelet therapy, VKA = vitamin K antagonist.
- a: At the exception of patient at very high bleeding risk.
- b: DAPT may be used if another indication supersedes that of carotid artery stenting such as acute coronary syndrome or percutaneous coronary intervention of less than 1 year.
- c: In case of recent minor stroke or TIA. A loading dose of aspirin (300 mg) and/or clopidogrel (300/600 mg) is recommended at the acute phase of stroke/TIA or during CAS.
- d: Stands for as long as it is well tolerated.

ACS = acute coronary syndrome; CAD = coronary artery disease; CLTI, chronic limb-threatening ischaemia; DAT = dual anti-thrombotic therapy; LEAD = lower extremity artery disease; NDACL = non-vitamin K oral anticoagulants; OAC = oral anticoagulation; VKA = vitamin K antagonist.

* DAT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in patients with recent acute coronary syndrome and/or percutaneous coronary intervention (<1 year), stenting of the last patent coronary artery, multiple coronary vessel disease in diabetic patients with incomplete revascularisation.

**Fig. 2: Antiplatelet therapy in patients with LEAD requiring oral anticoagulation [2]**

- ACS = acute coronary syndrome; CAD = coronary artery disease; CLTI: chronic limb-threatening ischaemia; DAT = dual anti-thrombotic therapy; LEAD = lower extremity artery disease; NDACL: non-vitamin K oral anticoagulants; OAC = oral anticoagulation; VKA = vitamin K antagonist.

* DAT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in patients with recent acute coronary syndrome and/or percutaneous coronary intervention (<1 year), stenting of the last patent coronary artery, multiple coronary vessel disease in diabetic patients with incomplete revascularisation.

**Fig. 3: Management of antithrombotic treatment in patients with carotid artery stenosis [2]**

- **DAPT = dual antiplatelet therapy, SAPT = single antiplatelet therapy, VKA = vitamin K antagonist.
- a: At the exception of patient at very high bleeding risk.
- b: DAPT may be used if another indication supersedes that of carotid artery stenting such as acute coronary syndrome or percutaneous coronary intervention of less than 1 year.
- c: In case of recent minor stroke or TIA. A loading dose of aspirin (300 mg) and/or clopidogrel (300/600 mg) is recommended at the acute phase of stroke/TIA or during CAS.
- d: Stands for as long as it is well tolerated.

ACS = acute coronary syndrome; CAD = coronary artery disease; CLTI: chronic limb-threatening ischaemia; DAT = dual anti-thrombotic therapy; LEAD = lower extremity artery disease; NDACL: non-vitamin K oral anticoagulants; OAC = oral anticoagulation; VKA = vitamin K antagonist.

* DAT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in patients with recent acute coronary syndrome and/or percutaneous coronary intervention (<1 year), stenting of the last patent coronary artery, multiple coronary vessel disease in diabetic patients with incomplete revascularisation.

**Fig. 2: Antiplatelet therapy in patients with LEAD requiring oral anticoagulation [2]**

- ACS = acute coronary syndrome; CAD = coronary artery disease; CLTI: chronic limb-threatening ischaemia; DAT = dual anti-thrombotic therapy; LEAD = lower extremity artery disease; NDACL: non-vitamin K oral anticoagulants; OAC = oral anticoagulation; VKA = vitamin K antagonist.

* DAT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in high-risk ischaemic patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomitant CAD; SAPT may be considered in patients with recent acute coronary syndrome and/or percutaneous coronary intervention (<1 year), stenting of the last patent coronary artery, multiple coronary vessel disease in diabetic patients with incomplete revascularisation.
Primary prevention of stroke or TIA

According to R. Mealli and E. Ricciti, the benefit observed in terms of reduction of ischaemic events balances the risk of bleeding and haemorrhagic stroke associated with the daily use of aspirin, if the risk of CV events is high [14]. Antiplatelet agents, other than aspirin, still have no evidence of benefit in asymptomatic patients with carotid stenosis [14].

Secondary prevention of stroke

Regarding secondary prevention, a systematic review of literature suggested that aspirin alone, combination of aspirin and diprydamole, clopidogrel, and trifusal could reduce the relative risk of stroke after a first event. In particular, the combination of aspirin and extended-release diprydamole reduces the relative odds of stroke, MI or vascular death by about 18% (OR 0.82, 95% CI: 0.74–0.91) compared with aspirin alone, without causing more bleeding events [10]. Early administration of aspirin in the acute phase of stroke or TIA was also shown to be safe and effective [10]. In the same meta-analysis, clopidogrel was still proven to be effective in reduction of major vascular events when compared to placebo (4.2% vs. 6.8% placebo; RR 0.61, 95% CI: 0.41–0.81). In the CAReSS trial, the efficacy of DAPT (aspirin plus clopidogrel) was compared to aspirin alone, in reducing asymptomatic embolisation in patients with recently symptomatic carotid stenosis, measured with microembolic signals (MES) detected by transcranial Doppler ultrasound. Patients treated with DAPT had lower MESs (RR 39.8%, 95% CI: 13.8–88.0, P<0.0044), fewer MESs per hour (90% CI: 31.6–78.2, P<0.001), and fewer strokes compared to patients treated with aspirin alone in the first week after stroke [11].

Acute treatment of TIA or minor stroke

The CHANCE trial, enrolling patients with TIA or minor stroke treated within 24 hours after the onset of symptoms, showed that DAPT was better than aspirin alone in reducing the risk of stroke in the first 90 days (8.2% vs. 11.7%, HR 0.68, 95% CI: 0.57–0.81, P=0.001) and did not increase the risk of haemorrhage (0.3% vs. 0.3%, P=0.73). There was no different incidence of moderate to severe haemorrhage in patients treated with aspirin monotherapy versus DAPT [13].

Conclusions

Despite an abundance of data demonstrating efficacy of antiplatelet therapy in coronary artery disease and cerebrovascular disease, there is a paucity of clinical information, clinical guidelines and randomised controlled studies in the PAD population. Hence, data on antiplatelet therapy in coronary interventions is frequently extrapolated to peripheral interventions. Another challenge that necessitates further trials specifically focused on different subsets of populations is related to the extreme variability of PADs scenarios: stable and unstable conditions, different treatment options (medical, endovascular and surgical), variable extension and localisation of artery disease.

References:
Research is a key building stone of any medical specialty, and the fast pace of change within interventional radiology makes it doubly so. Starting in 2013, CIRSE has been gradually redefining its role in IR research. In addition to pursuing its conventional role of disseminator and supporter of research, the society shifted towards becoming a collector of data, by officially developing an in-house research infrastructure tailored to high-quality observational studies.

With grants by our industry partners and guided by scientific Steering Committees, the CIRSE Clinical Research Department has since then successfully designed and conducted observational studies in post-market observation as well as national reimbursement settings.

With our clinical research operations and projects, the demands on our infrastructure have grown too, and we currently face new challenges in developing our service to be able to even better meet the demands for high-quality data collection in the IR community. Stay tuned for updates in 2020 or visit the Clinical Research Booth for more information.

CIRSE Research Network
- Hundreds of hospitals across Europe and North Asia, including 60+ Hospitals currently actively participating
- 13 countries
- 3 industry partners
- Health care professionals
  - a. IRs/CIRSE members
  - b. other specialties/non-CIRSE members

Visit us at our booth located in the entrance hall to find out about our projects and services in IR research.
CIREL

Key points
- Includes Central Image Review
- Population: all mCRC patients treated with LifePearl Microspheres
- Patient target: up to 500, 12 months minimum follow-up

Objectives
- Primary: To observe the real-life clinical application
- Secondary: To observe safety and effectiveness and Quality of Life

Multidisciplinary Steering Committee
- Co-Chairs: Prof. Philippe Pereira (SLK Klinikum Heilbronn GmbH, Germany) and Prof. Julien Taieb (Hôpital Européen George-Pompidou, France)

Status quo
- Data collection ongoing
- Drafting methodology paper
- Preparation of publication of 50-patient interim analysis

CIRT

Key points
- First CIRSE-sponsored study
- Population: all indications treated with SIR-Spheres Therapy
- Patient inclusion: 1,051 patients from 8 countries

Objectives
- Primary: To observe the real-life clinical application of SIR-Spheres Therapy
- Secondary: To observe safety and effectiveness and Quality of Life

Multidisciplinary Steering Committee
- Prof. Thomas Helmberger (Städtisches Klinikum München – Klinikum Bogenhausen, Germany)

Status quo
- Preparation of methodology paper
- Preparation of results publication

CIRT-FR

Key points
- Regulatory study in France: reports to the French ministry of health (HAS)
- Patient enrolment extended until August 2020
- Population: all indications treated with SIR-Spheres Therapy in France
- Patient target: 200-300, 24 months minimum follow-up

Objectives
- Primary: To observe the real-life clinical application
- Secondary: To observe safety and effectiveness and Quality of Life

Multidisciplinary Steering Committee
- Co-Chairs: Prof. Thomas Helmberger (Städtisches Klinikum München – Klinikum Bogenhausen, Germany) and Prof. Valerie Vilgrain (Hôpital Beaujon, France)

Status quo
- Data collection ongoing
- 30 centres included

CIEMAR Study design

The CIEMAR Emprint Microwave Ablation Registry (CIEMAR) will collect high quality data on microwave ablation using the Emprint Microwave Ablation System in a large multinational cohort. Design of the outcome measures was completed during the last scientific meetings around CIEMSE 2019 and the database is currently being implemented by the CIEMAR Steering Committee department using the OpenClinica data capturing system. With a target enrolment of 1,000 patients CIEMAR aims to be the largest data collection on MWA so far. Although CIEMAR is limited in terms of its explanatory power compared to a fully randomised controlled trial, the investigators are confident that the open, observational design will allow a clinically important assessment of the effectiveness of the therapy outside the ideal conditions created in controlled trials, achieve sub-sets of patients large enough to provide meaningful sub-group analysis as well as exploring how variability of the deliverance of treatment in routine practice may effect outcomes.

Project Outlook
Co-chaired by Prof. Philippe L. Pereira (SLK Klinikum Heilbronn GmbH, Germany) and Prof. Thierry de Baère (IR, France) the CIEMAR Steering Committee is comprised of experts in the field of interventional radiology and oncologic surgery from seven different countries. CIEMAR is launched and contract negotiations will commence with centres that fulfil the selection criteria. Centres deemed suitable for participation were contacted in October 2018 to establish initial interest in the study and make contracting more efficient once the study protocol was ratified. Until the start of patient enrolment in January 2020 the CIEMAR Steering Committee will finalise the CRF and the statistical analysis plan and explore the possibility of including a cost-effectiveness analysis in the scope of CIEMAR. Patient enrolment is planned to last for two years with a follow-up period of three years.

The study is sponsored by the CIRSE Society and independently managed by the CIRSE Clinical Research Department in conjunction with the CIEMAR Steering Committee. The study is funded by a research grant provided by Medtronic, the manufacturer of the Emprint Microwave Ablation System. The project is scheduled to run until 2025.

Key points
- Planned to be the largest data collection on MWA for liver metastases
- Population: all mCRC patients treated with Emprint Microwave Ablation
- Patient target: 1,000, 12 months minimum follow-up

Objectives
- Primary: To assess the effectiveness of microwave ablation in the liver
- Secondary: Evaluate Safety and Toxicity, Survival, Quality of Life and Health Economic aspects

Multidisciplinary Steering Committee
- Co-Chairs: Prof. Philippe L. Pereira (IR, Germany) and Prof. Thierry de Baère (IR, France)

Status quo
- Study protocol finalised
- Study launched
- Data collection to be started in January 2020

www.cirse.org/research/research-agenda/
Come join us to celebrate the end of another successful Annual Congress!

The CIRSE 2019 Dinner & Farewell Party will be held at Can Travi Nou restaurant, an authentic Catalan farmhouse situated in a picturesque rustic setting. You can look forward to a delicious three-course dinner, followed by a party in the compound’s beautiful garden which is sure to last until the early morning hours.

Dinner and party tickets
(include cocktail reception, dinner, complimentary drinks, entertainment): EUR 75 each

Party only tickets
(include free drinks and entertainment): EUR 25 each

Don’t miss out!
Buy your tickets at the “Hotel | Social Events | City Information” desk, located in the entrance hall of the congress centre.

CIRSE supports compliance with ethical standards. Therefore, CIRSE emphasises that the present offer (made by Kuoni Congress) is directed to participants of CIRSE 2019 and recommends that the participants who want to accept the present offer shall bear any and all costs in this context themselves. Kindly note that entrance to the CIRSE 2019 Dinner & Farewell Party is NOT included in the CIRSE 2019 registration fee!
Meet your partner in IR research –
CIRSE Clinical Research

CIRSE Research Network

IRs & Medical Specialists
8000 CIRSE Members
providing us with ideas and
benefiting from our research

Over 70 CIRSE Members/IRs
currently act as Primary Investigators
in CIRSE-sponsored studies.

Our multidisciplinary
Study Steering Committees
include:
- Oncologists
- Surgeons
- Nuclear Medicine
- Hepatologists

Over 60 Hospitals from
13 European Nations
From small, local medical centers to some
of the largest full-service hospitals in Europe,
wherever IR is performed in Europe, CIRSE
seeks to collect data.

Medical Device Manufacturers
Our research is only made possible through
the research grants provided by our trusted
partners in the medical device industry.

Partners & Service Providers
CIRSE partners with prestigious academic
institutions such as EORTC or FFCD and
contracts high-quality suppliers to get the
job done.

Visit us at our booth located in the entrance hall to find
out about our projects and services in IR research.

Whether you have an idea for a project, are a current CIRSE study investigator
(or would like to become one!) or work in the medical industry, we’re interested
to hear your unanswered questions and eager to help you find an answer.

Initiative Overview

CIRSE Registry for SIR-Spheres Therapy in France
CIRSE Registry for LifePearl Microspheres
CIRSE Registry for SIR-Spheres Therapy
CIRSE Emprint Microwave Ablation Registry
Becoming an IR – an interview with ETF Subcommittee member Robyn Benz

CIRSE: Let’s start from the beginning: why did you decide to study medicine and when did you first hear about IR?

Benz: Medicine was always the last subject I would have considered studying, but after two years at a school of fine arts I was longing for a more tangible education, and so I sought guidance. We collected all the subjects that interested me – I’m not even sure how medicine got on that list. I suppose I put it there because my dad, who is a radiologist, always thought it would be the right thing for me. I was asked to cross out the subjects that interested me least and seemed the least feasible to achieve as a future career. In the end, medicine was the last remaining item on the list, so I thought I might as well give it a try. I’m not sure when I first heard about interventional radiology. My dad had told us several stories about his time in interventional neuroradiology, I suppose that was the first time.

CIRSE: What inspired you to choose IR as your future career? Have you ever regretted your decision?

Benz: I’ve always liked working with my hands, the fiddlier the better, and I like to “do” things. Initially, I considered going into surgery, which I didn’t do for several reasons. I chose radiology because I liked the visual, analytical approach I always had in the back of my mind that this choice would leave the door open to IR, that seemed a good mix between the two specialties. I realised that I would have to step through that door during my fellowship in musculoskeletal radiology, where I started getting antsy after any more than two hours in front of the computer and I realised that between part of my day was when I got to perform arthrographies.

No, I don’t regret my choice at all. The only moment I have a hint of doubt is during on-call duty when the phone rings at 2 o’clock in the morning or when I’m still at work very late on a Friday night. But these hints of doubt are gone instantaneously when I think of the seemingly never-ending interpretation list in diagnostics, the gratitude the patients express when we were put in contact.

I haven’t trained in other places yet, but I will move to Montreal for another fellowship next year.

CIRSE: How many of your colleagues performing IR are women? Do you think that the IR gender gap is closing?

Benz: None of my colleagues are women, neither in Basel nor in Nice. I hope the gender gap is closing, but I think it will take at least one or two more generations of IRs and I’m not sure if it will ever close completely.

CIRSE: What would you suggest changing in order to make the field of IR more appealing to female physicians? How is the ETF contributing to this?

Benz: The two most common reservations I hear are radiation exposure and compatibility with children and family. I think we have shown that under the condition of adequate radiation protection the former is no longer of any real concern. The latter I believe is a biological as much as an issue of society. IR teams tend to be small. Therefore, a working IR will always be bound to frequent on-call duties. Compatibility of these on-call duties with childcare requires a partner who is willing and capable to back up childcare. This is true for both men and women, but I believe it is still rooted deep in former patriarchal societies and in the thoughts of many people that childcare is bound to be more of a female responsibility. I’m not sure there is much we can change about that. But I think it is important to rid IR off the reputation of being a male domain not meant for women. I was confronted with these prejudices quite a few times and it made me question my decision and feel not very welcome.

CIRSE: As your Swiss and performing interventional radiology in France – can you tell us more about why you decided to move from your home country? Have you trained in any other places?

Benz: During my fellowship at the University Hospital in Basel I got to work in almost all fields of IR, but some of the interventions were performed only in very small numbers. Therefore, I felt I was lacking experience in some areas of IR after my fellowship. I’ve always wanted to work abroad to expand my horizons and gain experience on a personal and professional level, and in Switzerland at least one year abroad is required for an academic career. So, I seized the opportunity to work with in Nice with Prof. Chevalier, who is a designated expert in the field of oncological IR, when we were put in contact.

CIRSE: What is the biggest achievement made by the ETF since you joined?

Benz: I joined the ETF at the end of 2017. I think every single one of us is working hard to support young IRs on a national level, but I believe the biggest achievement was to have CIRSE offer free registration for the CIRSE congress to all IR trainees and residents who submit an abstract, whether it is accepted or not. This makes IR and the knowledge being shared by all the experienced speakers very accessible.

ETF: When did you become a member of the ETF? What would you consider is the biggest achievement made by the ETF since you joined?

Benz: I joined the ETF at the end of 2017. I think every single one of us is working hard to support young IRs on a national level, but I believe the biggest achievement was to have CIRSE offer free registration for the CIRSE congress to all IR trainees and residents who submit an abstract, whether it is accepted or not. This makes IR and the knowledge being shared by all the experienced speakers very accessible.
Students in the Spotlight

We had a chance to speak with some of your peers about their interest in medicine and experiences studying throughout Europe. Meet today’s students studying in Croatia and the United Kingdom.

Nika Jemrić
Zagreb, Croatia
University of Zagreb Medical School

CIRSE: Why did you decide to study medicine and why are you interested in IR?
Nika: I decided I wanted to study medicine during my first year of high school. I wanted something where I could use my abilities and gain knowledge that would do some good. As I like both science and helping others, it was best of both worlds. IR is one of the most exciting and fastest developing fields in medicine. Its connection to technology and minimally invasive nature is what drew me in the most.

CIRSE: How did you hear about CIRSE?
Nika: I heard about CIRSE through friends and the Facebook page.

CIRSE: When did you hear about IR for the first time?
Nika: I first heard about IR during my internal medicine rotation in nephrology. One of the patients had renal artery stenosis and was sent to interventional radiology for stenting and I was sent to observe the procedure. It was my first clinical rotation and first encounter with lead aprons and radiation. The attending doctors helped us get dressed in lead and explained the procedure. It was all very exciting.

CIRSE: Why did you decide to study medicine and why are you interested in IR?
Nika: I decided I wanted to study medicine during my first year of high school. I wanted something where I could use my abilities and gain knowledge that would do some good. As I like both science and helping others, it was best of both worlds. IR is one of the most exciting and fastest developing fields in medicine. Its connection to technology and minimally invasive nature is what drew me in the most.

Krishanth Ganesan
Sheffield, United Kingdom
(Originally from Singapore)
University of Sheffield

CIRSE: Why did you decide to study medicine and why are you interested in IR?
Krishanth: I decided to study medicine as I liked science and wanted to make an impact on patient’s lives. I felt it would be meaningful to be able to do a job that can make a positive impact on people. I like IR as it seems to be the future of medicine with cutting-edge technology and is a quickly growing specialty. I enjoy anatomy and imaging and liked the idea of applying imaging for procedures.

CIRSE: When did you hear about IR for the first time?
Krishanth: I heard about IR after reading an article on a shortage of specialist surgeons that was compromising care in the United Kingdom, and looking IR up online to learn more. I found the procedures very novel and cutting-edge. I decided to then spend some time in IR with my local department and enjoyed it.

CIRSE: What kind of exposure do you get to IR at your university and within your undergraduate studies?
Krishanth: In my university, we have a one-week radiology placement. For students in the main teaching hospital, they may be able to spend one day with vascular IR. However, most students will not get any exposure to IR throughout medical school. I am currently the president of the Radiology Society at my university and am trying to improve the awareness of IR in the undergraduate level through career talks and posting interesting cases on the society’s Facebook page.

QUESTIONS OF THE DAY

Monday, September 9, 2019

Read today’s Congress News and make sure that you are one of the first two students to send the correct answers to students@cirse.org by 14:00 today!

Get inspired by reading the articles and win a voucher allowing you to choose up to 4 CIRSE Academy online courses!

1. Which cancer has been the proving ground for most immunotherapies?
2. There is a travel notice for Wednesday! What route do the police recommend you use to get around more easily?
3. PAD is an increasing burden worldwide. Name at least three factors that are contributing to this
4. Renal cell cancer is usually diagnosed when it is still confined to where?
5. In radiation protection, what does “ALARA” stand for?

IR Congress News is published as an additional source of information for all CIRSE 2019 participants. The articles and advertorials in this newspaper reflect the authors’ opinions. CIRSE does not accept any responsibility regarding their content.

Editors-in-Chief: Fabrizio Fanelli and Thomas Kroencke
Editorial Team: CIRSE Office (publications@cirse.org)
Graphics/Artwork: LOOP ENTERPRISES media / www.loop-enterprises.com
Lipiodol® efficacy & safety for improved overall survival in HCC

Endorsed by International HCC Treatment Guidelines

Guerbet
The CIRSE Annual Meeting has become the number one platform for minimally invasive image-guided procedures worldwide. Every year, key players in the field choose CIRSE to launch their innovative new products.

To find out more about the products being officially launched during CIRSE 2019, please visit the company booths in the Exhibition Hall. You will find a detailed floor plan overleaf! A full list of exhibitors and a floor plan can be found in your pocket guide, as well as via the CIRSE app.

Please note that the information has been provided by the corporate partners and does not reflect the opinion of CIRSE nor does it engage our responsibility.
**Cordis**

**MYNX CONTROL™ Vascular Closure Device: SECURE EXTRAVASCULAR CLOSURE**

MYNX CONTROL™ VCD provides active extravascular sealing and resorbability properties with a next-generation delivery system to maximize predictability, safety, and ease of use in sealing 5-7F femoral arterial access sites.

**Featuring:**

- A next-generation deployment system designed for predictability and ease of use with a 2-button design to simplify procedural steps
- A sheath catch that is compatible with the procedural sheath
- A tension indicator that provides visual confirmation of device position for proper sealant deployment
- Available in 5F as well as 6/7F sizes

**MYNX™ VCD has been clinically proven to reduce surgical complications, expedite recovery, shorten hospital stays, and increase patient comfort**.

Visit Cordis at booth #52 to learn more!

1 Prudes ML et al. MyoTemp for closure of antegrade puncture after percutaneous coronary intervention with same-day discharge. Vasc Endovasc Surg. 2017 Feb;51(2):67-72
4 Noor S et al. Successful reduction of surgeries secondary to arterial access site complications: a retrospective review at a single center with an extravascular closure device. Vasc Endovasc Surg. 2016 Jun;50(5):144-149
5 Pruski MJ Jr et al. MynxGrip for closure of antegrade puncture after peripheral interventions with same-day discharge.

**Philips Image Guided Therapy**

See clearly. Treat optimally.

Philips Azurion with FlexArm – the advanced suite that works around you. Philips Azurion 7 C20 with FlexArm is a revolutionary new approach to image-guided therapy, giving you the freedom to improve and grow your minimally invasive care.

This new ceiling-mounted system provides unlimited imaging flexibility for interventional radiology procedures, and exceptional positioning freedom for medical teams. All of this in a compact set-up, providing a highly cost-effective environment ready for the procedures of the future. By working around you, Philips Azurion with FlexArm helps optimize your suite performance, so you can deliver superior care.

Stop by the Philips booth to discover how Azurion with FlexArm empowers you to deliver better clinical outcomes in interventional radiology with:

- SmartPerfusion – perfusion imaging technology that provides you with an objective understanding of the impact of your patients’ treatment, helping you determine the outcome of CFI procedures.
- Philips Devices – offering the world’s first dedicated BTK IVUS platform to complement crossing solutions, atherectomy, drug-coated balloons and existing intravascular imaging (IVUS), for peripheral vascular, aorta, and deep venous procedures.

Join us at booth #3 and attend our Lunch Symposium on September 7th in Auditorium 2 (13:00 to 14:00) to discover more about FlexArm, SmartPerfusion, IVUS and many more. www.philips.com/flexarm

**Siemens Healthineers**

Transforming care delivery in image-guided therapy

Minimally invasive interventions hold a vast potential for growth and innovation: the ARTIS icono family was designed to help you realize that potential.

Multi-disciplinary usage between different clinical specialties and procedural intelligence for efficient workflows will allow to transform care delivery and expand precision medicine. Optimize your clinical operations with Case Flows, a sequence of system settings matching the diagnostic steps and treatment path.

For an extraordinary visibility of details regardless of patient size and C-arm angulation, ARTIS icono features OPTIQ, a novel CMR-based image chain. Driven by intelligent, self-adjusting algorithms, it results in constant image quality independent of angulation. ARTIS icono allows you to fully focus on the procedure.

ARTIS icono. An icon of innovation.

siemens-healthineers.com/artis-icono

The ARTIS icono system and its features are not commercially available in all countries. Future availability cannot be guaranteed.

**Terumo Interventional Systems**

MEDSPHERE

MEDSPHERE is a complete Radiofrequency Ablation System that allows the physician to ablate soft tissue in organs such as Liver, Kidney, Lung, Thyroid, as well as bone (osteoide osteoma). The system can be used with or without cooling system.

The versatility of MEDSPHERE can expand RFA ablation options, supporting the physician in choosing the best solution to approach each lesion and organ.

In fact, MEDSPHERE offers a wide range of treatment options:

- Two ablation modalities: Power Mode and Temperature mode
- Two electrode shapes: retractable Umbrella electrodes and Straight Cooled electrodes
- Various sizes: umbrella diameters 2cm, 3cm, 4cm, active tips from 5mm, 10mm, 15mm, 20mm, 30mm.
- Various lengths: 7cm, 10cm, 15cm, 20cm, 25cm

All electrodes have a detachable cable, for an easy positioning and management during CT operations.

An intelligent protection mechanism stops RF delivery in case of malfunctioning.

EXPAND YOUR RFA OPTIONS WITH TERUMO
Terumo Interventional Systems

QuiremScout®

QuiremScout® is the first and only CE-marked SIRT work-up product that utilizes the same technology as the therapeutic microspheres which aims to optimize patient selection and advance treatment planning.

QuiremScout® has been shown to be more accurate than the commonly used surrogate 99mTc-MAA at predicting lung shunting and intrahepatic distribution. It has also been proven to be clinically safe in a population of 82 patients.1

1 Elshof et al. 2014 EJNMMI
2 Dassen et al. 2018 CIRSE Abstract
3 Braat et al. 2017 Eur Radiol
Floor Plan

Discover more about these exciting new products: visit the company booths in the Exhibition Hall!

Links to the company websites can be found on the CIRSE website, www.cirse.org, or via the CIRSE app.